Phillip Minnis / Shutterstock.com (High Court of Australia, pictured)
7 October 2015Asia-Pacific
D’Arcy v Myriad: Australia’s High Court deals blow to natural product patents
Australia’s highest court has said that naturally occurring nucleic acid molecules are not patentable, overturning a lower court ruling.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Asia-Pacific
11 June 2015 The High Court of Australia has revealed it will hear oral arguments in the patent dispute between breast cancer survivor Yvonne D’Arcy and molecular diagnostic company Myriad Genetics on June 16 and 17.
Asia-Pacific
8 September 2014 Companies in Australia will be able to continue to patent human genes after a court rejected an appeal by a breast cancer survivor.
Editor's picks
Editor's picks
Asia-Pacific
11 June 2015 The High Court of Australia has revealed it will hear oral arguments in the patent dispute between breast cancer survivor Yvonne D’Arcy and molecular diagnostic company Myriad Genetics on June 16 and 17.
Asia-Pacific
8 September 2014 Companies in Australia will be able to continue to patent human genes after a court rejected an appeal by a breast cancer survivor.
Asia-Pacific
11 June 2015 The High Court of Australia has revealed it will hear oral arguments in the patent dispute between breast cancer survivor Yvonne D’Arcy and molecular diagnostic company Myriad Genetics on June 16 and 17.
Asia-Pacific
8 September 2014 Companies in Australia will be able to continue to patent human genes after a court rejected an appeal by a breast cancer survivor.